|
Volumn 98, Issue 12, 2007, Pages 418-424
|
Pharmacokinetics of gamma-hydroxybutylic acid (GHB) and gamma-butyrolactone (GBL), the anti-angiogenic metabolites of oral fluoropyrimidine UFT, in patients with gastric cancer.
a a a a a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
4 HYDROXYBUTYRIC ACID;
4-HYDROXYBUTYRIC ACID;
ANGIOGENESIS INHIBITOR;
ANTINEOPLASTIC AGENT;
GAMMA BUTYROLACTONE;
HYDROXYBUTYRIC ACID;
TEGAFUR;
UFT(R) DRUG;
UNCLASSIFIED DRUG;
URACIL;
AGED;
ARTICLE;
DRUG COMBINATION;
FEMALE;
HUMAN;
MALE;
METABOLISM;
MIDDLE AGED;
ORAL DRUG ADMINISTRATION;
STOMACH TUMOR;
4-BUTYROLACTONE;
ADMINISTRATION, ORAL;
AGED;
ANGIOGENESIS INHIBITORS;
ANTINEOPLASTIC AGENTS;
DRUG COMBINATIONS;
FEMALE;
HUMANS;
HYDROXYBUTYRATES;
MALE;
MIDDLE AGED;
STOMACH NEOPLASMS;
TEGAFUR;
URACIL;
|
EID: 40949117711
PISSN: 0016254X
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
Times cited : (7)
|
References (0)
|